Physician profile
Stuart B Levine
NPI 1881690675
$1,310.94
in general payments reported to CMS, 2019-2025
9 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2021: $117 · 2022: $89.83 · 2023: $304 · 2024: $307 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $280.04 | 2023-2025 | Proclaim, Esprit |
| Smith+Nephew, INC. | $254.82 | 2019-2024 | Collagenase Santyl, Oasis, Versajet |
| Acera Surgical, INC. | $150.07 | 2024 | Restrata Wound Matrix |
| Amgen INC. | $149.50 | 2025 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $121.92 | 2023 | Nuzyra |
| Horizon Therapeutics Plc | $117.14 | 2021 | |
| Integra Lifesciences Corporation | $109.76 | 2019 | |
| Grt US Holding, INC. | $89.83 | 2022 | |
| Kerecis Limited | $37.86 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.